



sanofi

Platelets are one side of ITP, but when we look at it from another angle, we see the

multiple dimensions of ITP

[Dear] [Dr] [Last Name],

ASH 2023 attendees explored the multiple dimensions of ITP at the Sanofi booth.

ITP is an autoimmune disorder characterized by low platelet counts. It can also result in easy bruising, mucosal bleeding, fatigue, and cognitive impairment. Patients with ITP also have a higher risk of cerebral microbleeds and thrombotic events.^{1,2}

How familiar are you with ITP, its complex pathophysiology,¹ and the ways it can affect your patients?

Question:

Autoreactive B cells and macrophages may contribute to the destruction and impaired production of platelets in people with ITP.¹ Which enzyme helps drive key processes in these cells?

Answer:

Bruton's tyrosine kinase (BTK)^{3,4}

Investigate the critical role BTK plays in regulating these processes:

[Learn more](#)

Question:

ITP affects the whole patient, not just their platelets.⁵⁻⁷ What else can be considered when understanding the impact of ITP on patients' QOL?

Answer:

Symptoms such as⁵⁻⁷:

- fatigue
- cognitive impairment
- anxiety

[Learn more](#)

Question:

In the Immune Thrombocytopenia World Impact Survey (I-WISH),* 58% of patients reported feeling fatigue at the time of their ITP diagnosis.⁸ Of those patients, how many said their fatigue was severe?

Answer:

73%

Fatigue can be a major burden for patients with ITP, but HCPs may not perceive fatigue at the same levels that the patients do.⁸

For a deeper look into I-WISH data:

[Learn more](#)

For a more comprehensive review of these and other dimensions of ITP:

[Visit UnderstandingITP.com](#)

*I-WISH was an online, cross-sectional survey of 1507 patients with ITP and 472 hematologists or hemato-oncologists who treat patients with ITP in 13 countries. The patient questionnaire collected information on demographics and diagnosis, symptoms of ITP, health-related quality of life (HRQOL) and emotion associated with ITP, impact of ITP on work, finances, and support, treatment received, and patient and physician relationship. The physician survey comprised 6 sections that collected information on demographics, diagnosis of ITP and patient caseload, symptoms of ITP, impact of ITP on aspects of patients' physical, emotional, HRQOL, social health, treatment patterns, and patient and physician relationship. There were 2 questions about the emotional impact of ITP and the responses were based on a 7-point Likert scale (1 = never, 7 = a great deal). There was 1 additional question on the need for professional support.⁵

ASH=American Society of Hematology; ITP=immune thrombocytopenia; QOL=quality of life.

References: **1.** Cooper N, Ghanima W. Immune thrombocytopenia. *N Engl J Med*. 2019;381(10):945-955. **2.** Cooper N, Morrison MA, Vladescu C, et al. Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. *Blood*. 2020;136(25):2875-2880. **3.** Zhu S, Gokhale S, Jung J, et al. Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets – beyond B lymphocytes. *Front Cell Dev Biol*. 2021;9:727531. **4.** Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton's tyrosine kinase in inflammatory and autoimmune pathologies. *Front Cell Dev Biol*. 2021;9:668131. **5.** Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISH): impact of ITP on health-related quality of life. *Am J Hematol*. 2021;96(2):199-207. **6.** Mitchell E, Frith J, Newton J. Fatigue and cognitive impairment in immune thrombocytopenic purpura remain stable over time: short report from a longitudinal study. *Br J Haematol*. 2019;186(5):777-781. **7.** Terrell DR, Neunert CE, Cooper N, et al. Immune thrombocytopenia (ITP): current limitations in patient management. *Medicina (Kaunas)*. 2020;56(12):667. **8.** Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISH): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. *Am J Hematol*. 2021;96(2):188-198.

sanofi

Sanofi
450 Water Street
Cambridge, MA 02141

[Unsubscribe](#) | [Legal Disclaimer](#) | [Privacy Policy](#) | [Contact Us](#)

Intended for U.S. Healthcare Professionals only.

© 2023 Genzyme Corporation. All rights reserved. Sanofi is a registered trademark of Sanofi or an affiliate.

MAT-US-2310768-v1.0-11/2023